Article (Scientific journals)
Vignette therapeutique de l'etudiant. Inhibiteur des SGLT 2 ou agoniste des récepteurs du GLP-1 chez un patient diabétique de type 2 avec maladie cardiovasculaire ?
Scheen, André; Paquot, Nicolas
2018In Revue Médicale de Liège, 73 (1), p. 43-50
Peer reviewed
 

Files


Full Text
rmlg201801_10.pdf
Publisher postprint (681.38 kB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
GLP; Heart failure; Liraglutide; Renal impairment; SGLT2 inhibitor; Type 2 diabetes; 1 receptor agonist; Empagliflozin
Abstract :
[en] Two classes of antidiabetic agents have shown a cardiovascular and renal protection in patients with type 2 diabetes and high cardiovascular risk. Empagliflozin, a sodium-glucose cotransporter type 2 (SGLT2) inhibitor, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, were granted a reduction of major cardiovascular events and mortality after the positive results of EMPA-REG OUTCOME and LEADER outcome trials, respectively. Protection mechanisms most probably differ between the two pharmacological classes and are perhaps complementary. The question that may arise in clinical practice is to know which drug should be selected between these two options in a patient with type 2 and established cardiovascular disease, before considering a potential combination. The aim of this article is to discuss about the best therapeutic choice according to the patient individual profile and the specificities of each molecule.
Disciplines :
Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Paquot, Nicolas ;  Université de Liège - ULiège > Département des sciences de la santé publique > Diabétologie, nutrition et maladies métaboliques
Language :
French
Title :
Vignette therapeutique de l'etudiant. Inhibiteur des SGLT 2 ou agoniste des récepteurs du GLP-1 chez un patient diabétique de type 2 avec maladie cardiovasculaire ?
Alternative titles :
[en] SGLT 2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and cardiovascular disease ?
Publication date :
2018
Journal title :
Revue Médicale de Liège
ISSN :
0370-629X
eISSN :
2566-1566
Publisher :
Université de Liège. Revue Médicale de Liège, Liège, Belgium
Volume :
73
Issue :
1
Pages :
43-50
Peer reviewed :
Peer reviewed
Available on ORBi :
since 26 March 2018

Statistics


Number of views
132 (2 by ULiège)
Number of downloads
111 (1 by ULiège)

Scopus citations®
 
3
Scopus citations®
without self-citations
0

Bibliography


Similar publications



Contact ORBi